Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-site, Prospective, Open-label, Long-term, Flexible Dose, Interventional Study to Evaluate the Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome

NCT02187809 is registered in ClinicalTrials.gov with H. Lundbeck A/S as lead sponsor.

NCT NCT02187809
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02187809 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-site, Prospective, Open-label, Long-term, Flexible Dose, Interventional Study to Evaluate the Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome
Lead sponsor
H. Lundbeck A/S
Phase
Phase 3
Overall status
Terminated
Start date
March 31, 2015
Completion date
October 31, 2015
Enrollment
3 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

dravet syndrome